Selected article for: "high risk and illness severity"
Author: Gupta, Kush; Gandhi, Shipra; Mebane, Alexander; Singh, Angelica; Vishnuvardhan, Nivetha; Patel, Eshan
Title: Cancer patients and COVID-19: Mortality, serious complications, biomarkers, and ways forward
  • Cord-id: 1r6ki6h2
  • Document date: 2020_12_13
    • ID: 1r6ki6h2
    Snippet: The SARS-CoV-2 (COVID-19) pandemic has particularly serious consequences for cancer patients, as they are at high risk for severe complications and mortality due to the virus since cancer patients are immunocompromised. Preliminary evidence suggests that patients with hematological, and metastatic malignancies are particularly susceptible to developing severe COVID-19 illness, which leads to poor prognosis. Biomarkers including C-reactive protein and interleukin-6 may be predictors of outcome an
    Document: The SARS-CoV-2 (COVID-19) pandemic has particularly serious consequences for cancer patients, as they are at high risk for severe complications and mortality due to the virus since cancer patients are immunocompromised. Preliminary evidence suggests that patients with hematological, and metastatic malignancies are particularly susceptible to developing severe COVID-19 illness, which leads to poor prognosis. Biomarkers including C-reactive protein and interleukin-6 may be predictors of outcome and, therefore, crucial in assessing COVID-19 illness severity in cancer patients. A patient-specific risk and benefit inventory should be completed, and expert guidelines consulted when deciding to continue or postpone therapeutic interventions. This review presents preliminary evidence of COVID-19 infection and its impact on cancer, as well as discussion of general guidelines for the treatment and management of cancer patients with COVID-19.

    Search related documents:
    Co phrase search for related documents
    • ace inhibitor and acute ards respiratory distress syndrome: 1, 2, 3, 4
    • ace inhibitor and lmwh weight heparin: 1
    • ace inhibitor and low molecular: 1
    • ace inhibitor and low molecular lmwh weight heparin: 1
    • ace inhibitor and low molecular weight heparin: 1
    • active status and acute ards respiratory distress syndrome: 1